Wegovy: A Weight Loss Drug with Significant Heart Benefits

A landmark study has found that the obesity drug Wegovy can reduce the risk of severe heart problems by 20%, paving the way for applications beyond weight loss. The study enrolled over 17,600 participants with preexisting cardiovascular disease and a body-mass index of 27 or greater. Those who received Wegovy experienced a lower rate of heart attacks, strokes, and heart-related deaths compared to those who received a placebo. Participants on Wegovy also saw improvements in inflammation, cholesterol, blood sugars, and blood pressure. However, the drug does come with side effects and high costs. Novo Nordisk has requested the FDA to include heart benefits on Wegovy's label.